Distribution, levels, and activation of MEK1 in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Extracellular‐signal‐regulated kinase (ERK) has been implicated in the pathogenesis of Alzheimer's disease (AD), but the upstream cascade leading to ERK activation has not been elucidated. In this study, we focused on one of the physiological activators of ERK, mitogen‐activated protein kinase (MAPK)/ERK kinase 1 (MEK1). Although there was no significant difference in the level and distribution of total MEK1 between AD and age‐matched control cases, increased levels of activated phospho‐MEK1 were specifically localized to neuronal intracytoplasmic granular structures in severe AD (Braak stage V–VI). The considerable overlap between MEK1 and its downstream effector, phospho‐ERK, suggests both a functional and mechanistic link. Nuclear localization of phospho‐MEK1 was a prominent feature in both mild AD cases (Braak stage III–IV) and control cases with limited pathology (Braak stage I–II). Since MEK1 is normally cytoplasmic due to the active export from nucleus because of the presence of nuclear export signal in its amino‐terminus, we suspect that the apparent nuclear accumulation of phospho‐MEK1 in AD patients at early stages suggests that abnormal nuclear trafficking may contribute to the pathogenesis of AD. By immunoblot analyses, phospho‐MEK1 was significantly increased in AD over control cases. Together, these findings lend further credence to the notion that the ERK pathway is dysregulated in AD and also indicate an active role for this pathway in disease pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“All cases were assessed on clinical and pathological criteria established by CERAD and an NIA consensus panel (Khachaturian 1985; Braak and Braak 1991; Mirra et al. 1991).”
MethodDineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462 · cited 1×
“…in degenerating neurons in AD (McShea et al. 1999; Perry et al. 1999; Ferrer et al. 2001b; Zhu et al. 2001a) and AbPP transgenic mice models (Dineley et al. 2001; Stein and Johnson 2002); Secondly, ERK is activated by amyloid-b in vitro (Rapoport and Ferreira 2000; Kuperstein and Yavin…”
BackgroundPei, J.-J., Braak, H., An, W.-L., Winblad, B., Cowburn, R. F., Iqbal, K., & Grundke-Iqbal, I. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00488-6 · Cited by 247
The Role of Extracellular Regulated Kinases I/II in Late-Phase Long-Term Potentiation
Rosenblum, K., Futter, M., Voss, K., Erent, M., Skehel, P. A., French, P., Obosi, L., Jones, M. W., & Bliss, T. V. P. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05432.2002 · Cited by 155 · cited 1×
“LTP-inducing stimuli increase the expression of ERK2 in the hippocampus and the proper activation and inactivation of ERKs are essential for hippocampal LTP induction (English and Sweatt 1997; Rosenblum et al. 2002).”
BackgroundMills, J., Laurent Charest, D., Lam, F., Beyreuther, K., Ida, N., Pelech, S. L., & Reiner, P. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09415.1997 · Cited by 134 · cited 1×
“Finally, ERK plays an important role in AbPP processing and secretion (Mills et al. 1997; Desdouits-Magnen et al. 1998).”
BackgroundHARTZLER, A., ZHU, X., SIEDLAK, S., CASTELLANI, R., AVILA, J., PERRY, G., & SMITH, M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00029-5 · Cited by 43
Self-citation
Cited by
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Alzheimer's disease: the two-hit hypothesis
Zhu, X., Raina, A. K., Perry, G., & Smith, M. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00707-0 · Cited by 426
Self-citationLiao, Y.-F., Wang, B.-J., Cheng, H.-T., Kuo, L.-H., & Wolfe, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402034200 · Cited by 389
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease
Bryan, K. J., Zhu, X., Harris, P. L., Perry, G., Castellani, R. J., Smith, M. A., & Casadesus, G. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-13 · Cited by 114
Self-citation
Metadata
- Authors
- Zhu, X., Sun, Z., Lee, H., Siedlak, S. L., Perry, G., & Smith, M. A.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2003-07
- Volume
- 86
- Issue
- 1
- Pages
- 136-142
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1496314348
- Cited by
- 62
- References
- 7
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distribution, levels, and activation of MEK1 in Alzheimer's disease. https://app.cochat.ai/papers/10.1046/j.1471-4159.2003.01820.x
- The paper
- Zhu, X., Sun, Z., Lee, H., Siedlak, S. L., Perry, G., & Smith, M. A. (2003). Distribution, levels, and activation of MEK1 in Alzheimer's disease. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2003.01820.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.